Akhil Ravi Named CEO of Aurigene Pharmaceutical Services
Dr. Reddy's has appointed Akhil Ravi as CEO for its wholly-owned subsidiary Aurigene Pharmaceutical Services effective Feb. 1, 2022.
Since joining Dr. Reddy's in 2018 from McKinsey, Ravi has served as Head of Strategy for Services and Active Pharmaceutical Ingredients (APIs), and headed the Sales of APIs in Europe. He holds a BTech degree in Chemical Engineering from IIT Bombay and an MBA from the Indian School of Business (ISB).
Deepak Sapra, CEO of API and Services at Dr. Reddy’s and Member of the Board at Aurigene, said: "Akhil is very well prepared for this role. He was instrumental in growing our API business through product development and an improved service experience for our B2B customers through digital platforms. His strong background in customer service, sales, strategy, and management make him an ideal leader for Aurigene, and we look forward to his accomplishments in this new role."
"Aurigene Pharmaceutical Services is a dynamic partner for global pharma companies. With its integrated services from clinical research up to commercial manufacturing for small and large molecules, it is able to significantly speed up the journey of an NCE/NBE (New Chemical and Biological Entities) to the patient," Ravi added.
